16.03.2024 | Research
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study
verfasst von:
Naokazu Nakamura, Nobuyoshi Arima, Teruhito Takakuwa, Satoshi Yoshioka, Kazunori Imada, Kentaro Fukushima, Masaaki Hotta, Shin-ichi Fuchida, Junya Kanda, Nobuhiko Uoshima, Yuji Shimura, Hirokazu Tanaka, Kensuke Ohta, Satoru Kosugi, Hideo Yagi, Satoshi Yoshihara, Ryosuke Yamamura, Yoko Adachi, Hitoshi Hanamoto, Hirohiko Shibayama, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Akifumi Takaori-Kondo, Junya Kuroda, Itaru Matsumura, Masayuki Hino, the Kansai Myeloma Forum
Erschienen in:
Annals of Hematology
Einloggen, um Zugang zu erhalten
Abstract
Elotuzumab-based regimens are sometimes selected for multiple myeloma treatment after daratumumab-based regimens. However, there has been insufficient discussion on the efficacy of elotuzumab after daratumumab. We used Kansai Myeloma Forum registration data in a multicenter retrospective evaluation of the efficacy of elotuzumab after daratumumab. Overall survival (OS) rate and time to next treatment (TTNT) were significantly worse in the cohort given elotuzumab after daratumumab (Dara cohort, n = 47) than in the cohort with no history of daratumumab administration before elotuzumab (No-Dara cohort, n = 80, OS: P = 0.03; TTNT: P = 0.02; best response: P < 0.01). In the Dara cohort, OS and TTNT rates were worse with sequential elotuzumab use after daratumumab than with non-sequential (OS: P = 0.02; TTNT: P = 0.03). In patients given elotuzumab < 180 days after daratumumab, OS (P = 0.08) and best response (P = 0.21) tended to be worse, and TTNT was significantly worse (P = 0.01), than in those given elotuzumab after ≥ 180 days. These findings were confirmed by subgroup analyses and multivariate analyses. Monoclonal-antibody-free treatment might be preferable after daratumumab-based regimens. If possible, elotuzumab-based regimens should be considered only ≥ 180 days after daratumumab use.